An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis (SPIRIT)



Status:Recruiting
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:40 - Any
Updated:4/6/2019
Start Date:September 24, 2018
End Date:November 17, 2021
Contact:US Biogen Clinical Trial Center
Email:clinicaltrials@biogen.com
Phone:866-633-4636

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis

The primary objective of this study is to evaluate the efficacy of BG00011 compared with
placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). The secondary objectives of
this study are: to evaluate the efficacy of BG00011 compared with placebo in participants
with IPF as determined by change in percent predicted forced (expiratory) vital capacity
(FVC); to assess progression-free survival in participants who receive BG00011 compared with
placebo; to assess the occurrence of IPF exacerbation in participants who receive BG00011
compared with placebo; to assess the incidence of absolute decline in FVC ≥10% in
participants who receive BG00011 compared with placebo; to assess the time to death or lung
transplantation in participants who receive BG00011 compared with placebo, and the
transplant-free survival rate at Week 26 and Week 52; to assess the time to non-elective
hospitalizations in participants who receive BG00011 compared with placebo; to assess
additional pulmonary function test (PFT) findings in participants who receive BG00011
compared with placebo; To assess performance on the 6 minute walk test (6MWT) in participants
who receive BG00011 compared with placebo; to evaluate the safety and tolerability of
BG00011; and to evaluate the serum concentration of BG00011.


Key Inclusion Criteria:

- Female subjects must be surgically sterile, postmenopausal (minimum 1 year without
menses), or agree to use 1 or more forms of highly effective contraception from the
time of signing of the informed consent form (ICF) until 3 months after the last
injection of study medication. Male subjects must also agree to use 1 or more forms of
highly effective contraception for either themselves or their partners from signing of
ICF until 4 months after last injection of study medication.

- IPF diagnosed based on modified ATS/ERS/JRS/ALAT IPF guideline for diagnosis and
management, within 3 years of Screening.

- Combination of high-resolution computed tomography (HRCT) pattern and, if one has been
obtained, surgical lung biopsy pattern, consistent with diagnosis of IPF.

- Carbon monoxide diffusion capacity (DLco) (corrected for hemoglobin): 30% to 79%
predicted of normal at Screening, with no clinically significant deterioration between
the Screening Visit and randomization, as determined by the Investigator.

- Forced (expiratory) vital capacity (FVC) ≥50% predicted of normal at Screening, with
no clinically significant deterioration between the Screening Visit and randomization,
as determined by the Investigator.

- If a subject is taking nintedanib or pirfenidone, they must be on a stable dose for at
least 8 weeks prior to randomization.

Key Exclusion Criteria:

- Unable to perform pulmonary functional tests (PFTs) or undergo HRCT procedure.

- Peripheral capillary oxygen saturation (SpO2) <90% at rest (if on oxygen
supplementation, must be ≤2 L/min at rest).

- Airway obstruction (i.e., prebronchodilator FEV1/FVC <0.7) or evidence of a
bronchodilator response as defined by an absolute increase of ≥12% and an increase of
≥200 milliliters (mL) in FEV1 or FVC, or both, after bronchodilator use, compared with
the values before bronchodilator use at Screening.

- End-stage fibrotic disease likely requiring organ transplantation within 12 months, or
if the subject has initiated active evaluation for organ transplantation.

- The extent of emphysema in the lungs exceeds fibrosis, based on central review of HRCT
scans.

- Body weight <60 kg at Screening.

- History of or ongoing malignant disease, including solid tumors and hematologic
malignancies, with the exception of basal cell carcinomas, squamous cell carcinomas,
and carcinoma in situ of the cervix that have been completely excised and considered
cured >2 years prior to Screening.

- Significant cardiac disease (e.g., New York Heart Association Class 3 or 4; myocardial
infarction within the past 6 months; unstable angina; coronary angioplasty or coronary
artery bypass graft within the past 6 months; uncontrolled atrial or ventricular
cardiac arrhythmias; or pulmonary hypertension requiring pharmacologic treatment).

- Clinical diagnosis of any connective tissue disease (including but not limited to
scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and
rheumatoid arthritis) or a diagnosis of interstitial pneumonia with autoimmune
features as determined by the Investigator.

- Other disease that may interfere with testing procedures or, in the judgment of the
Investigator, may interfere with study participation or may put the patient at risk
when participating in this study.

- Other unspecified reasons that, in the opinion of the Investigator or Biogen, make the
subject unsuitable for enrollment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
We found this trial at
21
sites
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Chesterfield, MO
Click here to add this to my saved trials
?
mi
from
Falls Church, VA
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Madison, WI
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Providence, RI
Click here to add this to my saved trials
?
mi
from
San Miguel de Tucumán,
Click here to add this to my saved trials